Looking Ahead in the Multiple Myeloma Treatment Landscape
Experts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.
EP: 1.Clinical Scenario: A 61-Year-Old Woman with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
EP: 2.Induction Treatment Regimens for Patients With Transplant-Eligible NDMM
EP: 3.Treatment Strategies for Patients With High-Risk NDMM
EP: 4.Clinical Scenario: A 68-Year-Old Man With Transplant-Ineligible NDMM
EP: 5.Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM
EP: 6.Factors for Consideration When Treating Frail Patients With Transplant-Ineligible NDMM
EP: 7.Bone Disease Prophylaxis in Patients With Transplant-Eligible NDMM
EP: 8.Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 9.Choosing Between Bispecific or CAR T-Cell Therapy for Patients With Multiple Myeloma
EP: 10.Toxicity Management in Patients With Multiple Myeloma
EP: 11.Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma
Now Viewing
EP: 12.Looking Ahead in the Multiple Myeloma Treatment Landscape
EP: 13.CAR T-Cell Therapy Vs Bispecific Antibodies As Multiple Myeloma Treatment
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
